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In the history of vaccine development, key observations
have gradually led to our ability to take rational approaches
toward the induction of protective immunity to microbial
pathogens. The earliest efforts consisted of inoculating le-
sion material into healthy individuals resulting in the then
inexplicable prevention of the development of similar dis-
ease. Centuries later, after researchers found that micro-
scopic forms were responsible for the major human diseases
such as tuberculosis and smallpox, vaccines consisting of in-
oculating weakened or attenuated organisms were devel-
oped. The discovery of the cell populations that mediate
antibody and cellular immune responses, followed by the
identification of the cytokine mediators of cellular immu-
nity and the ability to identify, isolate, purify, and produce
antigenic molecules of various pathogens has permitted a
rational approach toward vaccine development. Perhaps no
disease model has been more widely used to understand the
roles of cell populations and cytokines in mediating disease
susceptibility and resistance than the infection of inbred
 
mice with the 
 
Leishmania
 
 parasite (1). For example, BALB/c
 
mice infected subcutaneously with 
 
Leishmania major
 
 de-
velop nonhealing, disseminated, fatal infections, whereas
C57BL mice similarly infected are more resistant, and heal
their infections. In addition to susceptibility factors deter-
mined by host genetics, it has recently been appreciated
that the insect that transmits leishmania to humans may play
a key role in the establishment of infection. The study by
Valenzuela et al. in this issue (2) exploits this information in
what may prove to be a unique approach to vaccination.
 
Leishmania
 
 are protozoan parasites of macrophages, trans-
mitted to humans and mammalian reservoirs by small biting
insects known as sand flies. Several species of the parasite
cause human disease, manifested in a variety of forms rang-
ing from a single cutaneous lesion to fatal disseminated in-
fection of lymphoid and hematopoetic tissues. There are
two basic forms of the parasite: the promastigote, that de-
velops and is transmitted by the sand fly, and the amastigote
that multiplies inside of macrophages. An effective immune
response is one that limits parasite replication within mac-
rophages, limiting disease progression. This can be accom-
plished by prior immunization with the parasite or selected
parasite antigens. However, the sand fly itself may influence
the infection process by enhancing the ability of the pro-
mastigote to establish the initial macrophage infection. The
identification of components of the sand fly vector that are
capable of exacerbating leishmanial infections was made
more than a decade ago by Titus and Ribeiro, who dem-
onstrated that extracts of sand fly salivary glands increased
infectivity in mice (3). If vector components are indeed
necessary for establishing infection in the mammalian host,
then an indirect approach to immunizing against 
 
Leishmania
 
could be directed against relevant antigens of the insect
rather than those of the parasite. The study by Valenzuela
et al. identifies an insect component that may be used to
induce an immune response against the parasite.
 
The immunological basis for the increased infectivity of
 
Leishmania
 
 in association with salivary gland homogenate
from sand flies remains to be understood. Although the in-
duction of proinflammatory molecules is associated with
homogenate components, their role in the infection process
is not yet defined. However, some components of sand fly
salivary glands are amongst the most potent vasodilators (4),
which induce a large influx of nascent macrophage/mono-
cytic cells, the host cell for the parasite. 
 
Leishmania
 
 are sus-
ceptible to complement-mediated lysis, and it is to the para-
sites’ advantage to enter the macrophage in an expedient
 
manner. It is known that increased production of TGF-
 
 
 
and IL-10 are closely associated with disease susceptibility in
humans and in animal models (5–8). 
 
Leishmania
 
 are obligate
intracellular parasites of macrophages, and each of these cy-
tokines is associated with increasing virulence of this and
other pathogens. It is possible that induction of one or both
of these molecules by vector saliva components could in-
crease macrophage infection. Conversely, IL-12 and IFN-
 
 
 
are cytokines associated with resistance to leishmaniasis (9,
10). In a previous study by Sacks et al., it was demonstrated
that a powerful delayed-type hypersensitivity (DTH) re-
sponse was induced in mice by prior exposure to sand fly
bites (11). The DTH response was characterized by a mas-
sive cellular infiltrate, with T cells that produced IFN-
 
 
 
,
the effector cytokine most closely associated with limiting
parasite replication in macrophage, and was correlated with
reduced infections when the mice were subsequently bitten
by infected sand flies. The study is reminiscent of one con-
ducted in guinea pigs, in which Behin et al. elicited DTH
reactions by either chemical sensitization or bacille Cal-
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mette-Guérin (BCG) immunization and found that such
reactions could effectively decrease the infectivity of 
 
Leish-
mania
 
 at the DTH site (12).
The study by Valenzuela et al. tested components of the
sand fly saliva for their ability to induce a DTH response af-
ter a sand fly bite. One such protein, termed SP15, was ca-
pable of inducing a strong DTH response and protection
against leishmaniasis in the absence of antibody, while
other fractions of sand fly saliva appeared to be less effec-
tive. Histologically, the DTH response induced by immu-
nization with SP15 was characterized by massive infiltrates
of neutrophils and eosinophils, similar to the response in-
duced by the bite itself. This is unlike the typical DTH in-
duced by bacterial antigens, such as the tuberculin reaction,
which is predominantly a mononuclear cell infiltrate, and
calls into question the immunological basis for the anti-
leishmanial activity observed. It has long been recognized,
for example, that several histological forms of DTH exist
(13, 14). The argument against the role of antibody in the
protection induced by immunization with SP15 comes
from the observation that protection was achieved in B
cell–deficient mice. Further characterization of sand fly
components and perhaps passive transfer experiments could
test the authors’ hypothesis that the protective DTH can be
induced by any protein in the saliva, or if there is a poten-
tially important role for antigen specificity such as in the
classic DTH reaction induced by mycobacteria (15).
Active immunization against leishmaniasis has been go-
ing on for centuries. The original version of a human vac-
cine consisted of inoculating lesion material into a naive in-
dividual using a thorn. The procedure was designed to
produce a mild disease to prevent more severe disfigure-
ment after subsequent natural exposure. During the past
two decades, a significant amount of work has been fo-
cused on prophylactic vaccine approaches designed to pre-
vent disease progression in mice infected with 
 
Leishmania
 
.
Approaches have included the use of whole attenuated par-
asites, parasite extracts, and of leishmanial antigens deliv-
ered as genes or proteins. Such approaches have met with
moderate to spectacular success in mouse models (16, 17).
Human vaccine trials using whole parasite preparations
have met with partial success (18), indicating that an effec-
tive human vaccine for leishmaniasis may be possible once
the appropriate immune response targets are identified.
Until now, the effort has been focused on antigens of the
 
Leishmania
 
 parasite.
Although the vast majority of vaccines have been di-
rected against antigens of the infectious agent transmitted
by the arthropod vector, other vaccine approaches have
been directed to the arthropod itself. For example, success
with vaccines against tick saliva has been achieved in cattle,
and a vaccine against fleas has been developed for dogs.
However, the concept of using nonparasite components to
induce a specific immune response designed to attack the
parasite and decrease infection through nonspecific means
is a new and potentially exciting approach toward vaccina-
tion against vector-borne pathogens. The identification of a
specific salivary gland component capable of inducing the
 
tissue reaction that leads to decreased infection is an impor-
tant finding and will aid in our understanding of host–vec-
tor interactions at the molecular level. If this component is
conserved among multiple species of sand fly, one could
envision the development of a vaccine capable of protect-
ing against multiple 
 
Leishmania
 
 species by immunizing with
a single vector protein. Persons living in endemic regions
would be repeatedly boosted when bitten by both infected
and uninfected insects. However, although it is possible
that such an approach could limit the severity of disease, it
would not likely be totally protective. In hyperendemic ar-
eas, there is often a high degree of exposure to bites from
uninfected sand flies, yet disease incidence is high. None-
theless, it is possible that sand fly molecules could be con-
sidered as components of a vaccine, together with parasite
antigens. However, any approach using sand fly proteins as
vaccine components must take into consideration a vaccine
formulation that will induce a nonpathologic DTH re-
sponse. The cellular infiltrate observed after immunization
with SP15 suggests elements of an allergic nature, with po-
tential implications of provoking adverse reactions in indi-
viduals with atopic reaction through this type of immuni-
zation approach.
An effective leishmaniasis vaccine will be one that pre-
vents the development of disease. The distinction between
vaccines designed to prevent establishment of infection ver-
sus those designed to prevent disease is an important one. A
decrease in infection, such as was achieved through the
prior exposure to sand fly bites or injection of purified pro-
tein, will not necessarily confer immunity to the parasite it-
self or prevent subsequent disease progression. In the guinea
pig study of Behin et al. (12), the decreased infectivity in-
duced by a DTH response did not eliminate infection, as
metastatic lesions developed later in initially protected ani-
mals, nor did it confer immunity to subsequent challenge
given in the absence of a DTH response. This latter prob-
lem may not occur in nature, where the only exposure to
infection that humans receive is in conjunction with sand
fly proteins. Thus, a DTH response would theoretically ac-
company each exposure to infection. The debate of infec-
tion versus disease is reminiscent of that surrounding the
malaria sporozoite vaccine. As the sporozoite is the infective
form transmitted by the mosquito, an effective immune re-
sponse against it confers immunity in mice. However,
should sporozoites escape this immune response, disease will
occur, as no immunity has been induced against the tissue
stages of the parasite. Similarly, 
 
Leishmania
 
 has a tissue stage
that is responsible for pathology and is distinct from the pro-
mastigotes transmitted by the sand fly. Thus, vaccines that
only prevent infection and do not establish immunity to tis-
sue parasites may bear a risk. On the other hand, it is possi-
ble that immunizing against sand fly components could pro-
duce a low grade infection, with a degree of immunity to
the amastigote tissue stage sufficient to prevent disease. Such
a state of immunity is the norm in humans infected with
leishmania; most infections are subclinical. Perhaps limiting
the number of surviving parasites after exposure via a DTH
reaction is why there are so many asymptomatic human in- 
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fections in certain endemic foci. Furthermore, there is the
unexplained observation that humans living in endemic ar-
eas often have milder lesions than those who come into en-
demic areas from outside the region. This comparative resis-
tance could be explained by a recall response to vector
components. Ideally, through a combination of vaccine
components directed against both vector and pathogen tar-
gets, safe, effective, and long-lasting immunity can be
achieved. Consideration of the vector and the pathogen as
an integrated unit in the infectious process represents a
change in our thinking with regard to vaccine development.
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